SMSoren Maret

Soren Maret

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Soren Maret has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Audrey E. Hendricks

    Department of Biomedical Informatics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA

    1 shared publication
  • Chang Liu

    Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO, USA

    1 shared publication
  • Daniel Frank

    Department of Medicine-Infectious Disease, University of Colorado School of Medicine, Aurora, CO, USA

    1 shared publication
  • Edward L. Melanson

    Division of Endocrinology, Metabolism, and Diabetes, University of Colorado Anschutz, Aurora, CO, USA

    1 shared publication
  • Jennifer F. Kemp

    Department of Pediatrics, Section of Nutrition, University of Colorado School of Medicine, Aurora, CO, USA

    1 shared publication
  • Matthew R. Olm

    Department of Microbiology and Immunology, Stanford University School of Medicine, Stanford, USA

    1 shared publication

Latest Publications

  • Open Access

    IgA Targeting in the Infant Gut Is Modulated by Diet and Increasingly Directed Towards Persistent Species

    by Jing Qian, Parsa Ghadermazi, Soren Maret, Jennifer F. Kemp, Daniel Frank, Edward L. Melanson, Audrey E. Hendricks, Nancy Krebs, Minghua Tang, Matthew R. Olm

    Background: IgA is the dominant antibody in the human gut and a key regulator of host-microbe interactions. Infants begin to produce IgA at around 6 months old and receive large quantities of IgA via human milk, but technical limitations have prevented species-level characterization of IgA binding in early life. This has left basic knowledge gaps about which species are targeted by IgA in infancy, and how modifiable lifestyle factors like breastfeeding and complementary feeding impact IgA targeting. Results: Here we adapt Metagenomic Immunoglobulin Sequencing (MIg-Seq) for low-biomass infant fecal samples and apply this optimized protocol to 32 longitudinal samples from 16 infants enrolled in the MINT trial, a four-arm randomized controlled trial comparing meat-based, dairy-based, plant-based, and reference complementary feeding patterns, with fecal sampling at 6 and 12 months (pre and post intervention). Infant IgA targeting mirrors adults at the phylum level, with both age groups showing significantly higher IgA targeting of Pseudomonadota and lower targeting of Bacteroidota relative to other phyla. During the substantial microbiome compositional shifts noted between 6 and 12 months, IgA targeting is significantly more stable than the microbiome itself. Among persistent colonizers, IgA targeting strengthens significantly from 6 to 12 months, with the most pronounced effect observed for Bifidobacterium , a finding robust across all dietary arms and feeding modes. The feeding arm to which infants were enrolled was not significantly associated with IgA binding, but several nutrient-specific associations were discovered. Animal-derived nutrients, particularly cholesterol, are strongly positively correlated with IgA targeting of Bifidobacterium longum , while plant-derived carotenoids are positively associated with IgA targeting of Flavonifractor plautii and Ruminococcus gnavus . Conclusions: This study introduces an experimental and computational framework for species-level IgA profiling in the infant gut. The progressive strengthening of IgA targeting of Bifidobacterium and other beneficial persistent colonizers suggests a role for IgA in reinforcing beneficial microbes during infancy. The nutrient-specific dietary effects on IgA targeting reveal the immunological consequences of the complementary feeding period, and highlight a contrast between animal-versus plant-based diets. Together, these findings point to early nutritional interventions and IgA-based therapeutics as promising tools for promoting healthy immune-microbiome development.